Carl Zeiss Meditec AGXSWX:AFX +0.48%67 5-Year Yield-on-Cost % is 2.74 as of Jul. 03, 2026, which is 119% above its 10-year median of 1.25. GuruFocus rates XSWX:AFX with a GF Score™ of 67/100 and a GF Value™ of CHF66.58 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 328 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks better than 56.71% on this metric.
Carl Zeiss Meditec AG's yield on cost for the quarter that ended in Dec. 2025 was 2.74.
The historical rank and industry rank for Carl Zeiss Meditec AG's 5-Year Yield-on-Cost % or its related term are showing as below:
XSWX:AFX'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.37 Med: 1.25 Max: 3.48
Current: 2.74
During the past 13 years, Carl Zeiss Meditec AG's highest Yield on Cost was 3.48. The lowest was 0.37. And the median was 1.25.
XSWX:AFX's 5-Year Yield-on-Cost % is ranked better than 56.71% of 328
companies
in the Medical Devices & Instruments industry
Industry Median: 2.325
vs XSWX:AFX: 2.74
Carl Zeiss Meditec AG (XSWX:AFX) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Carl Zeiss Meditec AG 5-Year Yield-on-Cost % Related Terms
XSWX:AFX vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carl Zeiss Meditec AG 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Carl Zeiss Meditec AG's 5-Year Yield-on-Cost % falls into.
Carl Zeiss Meditec AG 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Carl Zeiss Meditec AG (XSWX:AFX) has a 5-Year Yield-on-Cost % of 2.74 as of Jul. 03, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Carl Zeiss Meditec AG and its competitors. This is 119% above median its historical median of 1.25. Over the past decade, Carl Zeiss Meditec AG's 5-Year Yield-on-Cost % has ranged from 0.37 to 3.48. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #142 out of 328 companies in the Medical Devices & Instruments industry, placing it in the top 43.3%.
Is Carl Zeiss Meditec AG's 5-Year Yield-on-Cost % too high?
Carl Zeiss Meditec AG's current 5-Year Yield-on-Cost % of 2.74 is 119% above median its 10-year median of 1.25. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 3.48. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.33. Carl Zeiss Meditec AG's value of 2.74 is 17.8% above this industry median. Based on the distribution chart, Carl Zeiss Meditec AG ranks #142 out of 328 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Carl Zeiss Meditec AG has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #142 out of 328 companies for 5-Year Yield-on-Cost %. This puts Carl Zeiss Meditec AG in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.33. Carl Zeiss Meditec AG's value of 2.74 is 17.8% above this benchmark. Historically, Carl Zeiss Meditec AG's own 5-Year Yield-on-Cost % has ranged from 0.37 to 3.48 over the past decade. While the company's 10-year median is 1.25 vs. the industry median of 2.33, Carl Zeiss Meditec AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.33, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carl Zeiss Meditec AG's current 5-Year Yield-on-Cost % of 2.74 is 17.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Carl Zeiss Meditec AG and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current 5-Year Yield-on-Cost % is 2.74, which is 119% above median its own 10-year median of 1.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF66.58, compared to a current price of CHF25.22 — trading 62.1% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.74, which is 119% above median its 10-year median of 1.25 and 17.8% above the Medical Devices & Instruments industry median of 2.33. Carl Zeiss Meditec AG's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current 5-Year Yield-on-Cost % is 2.74 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of CHF25.22 is trading 62.1% below its estimated GF Value™ of CHF66.58.
GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.
Key valuation signals for XSWX:AFX:
5-Year Yield-on-Cost %: 2.74 (119% above median its 10-year median of 1.25)
GF Value™: CHF66.58 vs. price of CHF25.22 (62.1% below fair value)
Industry Position: 17.8% above the Medical Devices & Instruments median (#142 of 328)
No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
67GF Score
Get the complete analysis for XSWX:AFX
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:AFX has been successfully added to your 